NEJM - Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

NEJM - Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured_coronavirus

8 de setembro de 2020

Categorias

Categorias

Arquivo de Notícias

Arquivo